Pediatric drug development: From “wild west” to model-informed confidence
Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…
CertaraFebruary 11, 2026
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…
CertaraFebruary 2, 2026
How model-informed drug development (MIDD) strengthens drug asset valuation and answers the questions investors care about most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
CertaraJanuary 26, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…
CertaraJanuary 22, 2026
Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy
Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…
CertaraJanuary 22, 2026
Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies
Watch this on-demand webinar featuring former regulators as they share global regulatory trends and clinical…
CertaraJanuary 14, 2026
Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data
Learn how to interpret screening assay data to predict clinical off-target risk with ToxStudio® and…
CertaraJanuary 13, 2026
Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development
Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) have historically existed at the two ends of…
CertaraJanuary 7, 2026
